Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 14Breast 5Other hematologic neoplasm 3Sarcoma 2Gynecologic 2Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Recurrence 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × copanlisib × Sarcoma × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Swiss Cancer Institute

Phase 1 Terminated
7 enrolled
LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡